# **Special Issue**

# Signaling Pathways in Liver Fibrosis Process

# Message from the Guest Editor

Hepatic fibrogenesis is a complex process driven by a variety of pathogenic signaling transduction processes modulating the biology in parenchymal and nonparenchymal liver cells. Most important are cytokine and chemokine networks that orchestrate an inflammatory response that leads to the recruitment and activation of distinct leukocyte subsets. Moreover, the different molecular mediators target specific signaling branches that lead to increased formation of extracellular matrix. Simultaneously, different classes of reactive oxygen species are formed, resulting in enhanced oxidant stress and liver cell damage. Persistent liver damage results in sequential progression from inflammation to fibrosis, cirrhosis, and hepatocellular carcinoma. Currently, there is a great deal of basic and clinical research ongoing to interrogate core molecular pathways underlying fibrosis because early intervention is of paramount importance.

In this Special Issue of Livers, I cordially invite you to contribute, in the form of original research articles, reviews, or shorter perspective articles, on all aspects related to the theme of "Signaling Pathways in Liver Fibrosis Process".

### **Guest Editor**

Prof. Dr. Ralf Weiskirchen Institute of Molecular Pathobiochemistry. E

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany

# Deadline for manuscript submissions

closed (31 March 2022)



# Livers

an Open Access Journal by MDPI

Impact Factor 2.4 CiteScore 3.2



mdpi.com/si/95351

Livers Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 livers@mdpi.com

mdpi.com/journal/

livers





# Livers

an Open Access Journal by MDPI

Impact Factor 2.4 CiteScore 3.2



livers



# Message from the Editor-in-Chief

### Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA

### **Author Benefits**

### **High Visibility:**

indexed within ESCI (Web of Science), Scopus, EBSCO, and other databases.

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 27.2 days after submission; acceptance to publication is undertaken in 6.6 days (median values for papers published in this journal in the second half of 2024).

#### **Recognition of Reviewers:**

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

